

## SCOPE DEFINITION

**Guideline Title:** *Newborn bloodspot screening (NBS)*

Scope framework	
<b>Population</b>	<i>Which group of people will the guideline be applicable to?</i> Newborn babies
<b>Purpose</b>	<i>How will the guideline support evidence-based decision-making on the topic?</i> <ul style="list-style-type: none"> <li>Support newborn screening within relevant national and state frameworks, and legislation</li> <li>Identify relevant evidence related to newborn bloodspot screening and management</li> </ul>
<b>Outcome</b>	<i>What will be achieved if the guideline is followed?</i> <i>(This is not a statement about measurable changes / not SMART goals)</i> <ul style="list-style-type: none"> <li>Provide evidence informed information about newborn bloodspot screening</li> <li>Support: <ul style="list-style-type: none"> <li>Best practice management of newborn screening practices</li> <li>Early identification/diagnosis of conditions and diseases</li> </ul> </li> </ul>
<b>Exclusions</b>	<i>What is not included/addressed within the guideline</i> <ul style="list-style-type: none"> <li>Routine baby care</li> <li>Management (diagnosis, investigation, ongoing treatment) of diseases/conditions screened</li> <li>Protocols for local collection of NBS after discharge</li> <li>Protocols for local dispatch of cards</li> <li>Laboratory testing and interpretation of NBS cards</li> <li>Elements specific to Queensland Clinical Guideline <i>Standard care</i></li> </ul>

## Clinical questions

Question	Likely Content/Headings/Document Flow
<b>Introduction</b>	Communication Clinical standards Service levels responsibilities
1. What is newborn bloodspot screening (NBS)?	<ul style="list-style-type: none"> <li>Overview</li> <li>Description and overview of diseases/conditions screened <ul style="list-style-type: none"> <li>Genetic</li> <li>Metabolic</li> <li>Hormonal</li> <li>Other</li> </ul> </li> </ul>
2. What preparation is required for NBS screening?	<ul style="list-style-type: none"> <li>Parental engagement <ul style="list-style-type: none"> <li>Antenatal discussion</li> <li>Written and verbal information (including future use of sample cards)</li> <li>Informed consent process (including benefits of test and risks of declining)</li> </ul> </li> <li>Review of clinical history <ul style="list-style-type: none"> <li>Family history of genetic, metabolic, hormonal or other diseases/conditions</li> <li>Maternal (e.g. antenatal steroid use, previous fetal death)</li> </ul> </li> </ul>
3. What information is required about the baby?	<ul style="list-style-type: none"> <li>Baby clinical status (e.g. well and preterm)</li> <li>Date and time of birth <ul style="list-style-type: none"> <li>Feeding status</li> </ul> </li> </ul>

Available from: [www.health.qld.gov.au/qcg](http://www.health.qld.gov.au/qcg)

Document Number: SC24.53-1-V1-R29

Effective date: February 2024 | Review date: February 2029



State of Queensland (Queensland Health 2024)

Clinical  
Excellence  
Queensland



		<ul style="list-style-type: none"> <li>○ Intravenous fluids (e.g. glucose, TPN)</li> <li>○ Received a blood transfusion</li> <li>○ Ambiguous genitalia</li> <li>● Feeding history : timing, milk type, if NBM, LBW/unwell</li> </ul>
4.	What care is indicated for baby before, during and after procedure?	<ul style="list-style-type: none"> <li>● Comfort measures: <ul style="list-style-type: none"> <li>○ Non-pharmacological breastfeeding, expressed breast milk, skin to skin, swaddling</li> <li>○ Pharmacological (e.g. sucrose)</li> </ul> </li> <li>● Positioning (foot hanging down)</li> <li>● Warmth</li> <li>● Site monitoring/care</li> </ul>
5.	What are the best practice recommendations for NBS sample collection and storage prior to dispatch?	<ul style="list-style-type: none"> <li>● Equipment required (appendix)</li> <li>● Completion of card information (example card in appendix)</li> <li>● Procedure <ul style="list-style-type: none"> <li>○ ID checks</li> <li>○ Skin preparation</li> <li>○ Correct collection sites</li> <li>○ Sampling technique</li> <li>○ Management of sampling site (e.g. haemostasis, observation)</li> </ul> </li> <li>● Documentation of collection, e.g. <ul style="list-style-type: none"> <li>○ NBS card</li> <li>○ Baby's personal health record ('red book')</li> <li>○ Clinical pathway</li> </ul> </li> <li>● Process to maintain integrity of sample before, during and after dispatch (e.g. drying, storing)</li> </ul>

**Potential areas for audit focus (to be refined during development)**

*Audit items will relate to the desired outcomes and the clinical questions*

- What is the proportion of repeat screens due to poor sample collection?
- What is the proportion of positive screens followed up within 24 hours of notification?
- What is the proportion of repeat screens followed up within 24 hours of notification?